article thumbnail

STAT+: Wearable devices generate powerful data but it’s not useful to doctors, yet

STAT

“Yesterday, I saw a patient with type 2 diabetes who has a continuous glucose monitor, and so she’s been tracking her blood sugar every five minutes,” said Ida Sim, a primary care physician and chief research informatics officer at the University of California, San Francisco.

article thumbnail

Insulin Storage and Beyond Use Dates – Free Downloadable PDF

Med Ed 101

Insulin Storage and Beyond Use Dates Free PDF should be a vital resource designed to help healthcare […] The post Insulin Storage and Beyond Use Dates – Free Downloadable PDF appeared first on Med Ed 101.

Diabetes 111
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

How Your Pharmacy Can Participate in American Diabetes Month

Digital Pharmacist

November is American Diabetes Month – a time to come together to spread awareness about diabetes prevention and management. In this blog post, we’ll explore key ways pharmacies can actively participate in American Diabetes Month.

Diabetes 105
article thumbnail

Free Download – 2022 Diabetes Guidelines Cheat Sheet

Med Ed 101

I recently blogged about my thoughts on the new diabetes guidelines. After that post, my friend Derek Borkowski who is the founder of Pyrls.com messaged me to offer followers of the Meded101 blog a free download. He’s put together a phenomenal resource with his 2022 Diabetes Guidelines Cheat Sheet.

article thumbnail

LyGenesis and Imagine Pharma partner for type 1 diabetes therapies development

Pharmaceutical Technology

Clinical-stage biotechnology firm LyGenesis has formed a joint research collaboration with Imagine Pharma to develop new cell therapies for type 1 diabetes (T1D). In June 2022, the company discovered T1D AIPCs, a critical component to treat T1D through autologous cell transplantation.

article thumbnail

Vertex signs licence deal with CRISPR Therapeutics for diabetes therapies

Pharmaceutical Technology

Vertex Pharmaceuticals has signed a new non-exclusive licensing agreement with CRISPR Therapeutics to expedite the development of its hypoimmune cell therapies to treat type 1 diabetes (T1D). A Phase I/II study of VCTX211 has been commenced and is currently ongoing. It originated under the partnership of CRISPR Therapeutics and ViaCyte.

article thumbnail

Novo Nordisk: Prevention, digital tools and collaboration to define the future of diabetes

pharmaphorum

In our latest UK Leaders article Pinder Sahota, UK general manager at Novo Nordisk, tells us how he hopes to bring the NHS and pharma together to improve outcomes in diabetes and other long-term conditions. Collaborating to prevent diabetes. We’ve got two such projects in the UK, in Leicester and Manchester,” says Sahota. “We

Diabetes 111